Table 3. A comparison between clinical characteristics of patients with somatic BRCA1/2 variants and non-carriers.
| Characteristics | Non-carriers No. (n = 385) | No. of patients with somatic BRCA1/2 P variants (n = 9) | No. of patients with Somatic BRCA1/2 VUS (n = 8) | |||||
|---|---|---|---|---|---|---|---|---|
| BRCA1/2 (n = 9) | P a | BRCA1 (n = 3) | P a | BRCA2 (n = 6) | P a | |||
| Age at diagnosis (y, mean±SD) | 50.7±10.3 | 49.7±10.4 | 0.77 | 42.0±12.1 | 0.15 | 53.5±7.9 | 0.51 | 51.5±6.0 |
| Family history of breast cancer | ||||||||
| Yes | 12 | 0 | 1.00 | 0 | 1.00 | 0 | 1.00 | 0 |
| No | 373 | 9 | 3 | 6 | 8 | |||
| Menopause at diagnosis | ||||||||
| Postmenopause | 176 | 5 | 0.74 | 1 | 1.00 | 4 | 0.42 | 4 |
| Premenopause | 206 | 4 | 2 | 2 | 4 | |||
| Molecular subtype | ||||||||
| Luminal A | 49 | 0 | 0.29 | 0 | 0.11 | 0 | 0.63 | 0 |
| Luminal B | 218 | 7 | 1 | 6 | 7 | |||
| HER2+ | 57 | 0 | 0 | 0 | 0 | |||
| TN | 48 | 1 | 1 | 0 | 1 | |||
| ER-PR+ | 13 | 1 | 1 | 0 | 0 | |||
| ER | ||||||||
| Positive(>1%) | 274 | 7 | 1.00 | 1 | 0.20 | 6 | 0.19 | 7 |
| Negative | 111 | 2 | 2 | 0 | 1 | |||
| PR | ||||||||
| Positive(>1%) | 266 | 7 | 0.73 | 2 | 1.00 | 5 | 0.67 | 5 |
| Negative | 119 | 2 | 1 | 1 | 3 | |||
| Ki67 | ||||||||
| <14% | 68 | 2 | 0.67 | 1 | 0.45 | 1 | 1.00 | 0 |
| ≥14% | 315 | 7 | 2 | 5 | 8 | |||
| HER2 | ||||||||
| Positive | 130 | 0 | 0.03 | 0 | 0.55 | 0 | 0.18 | 2 |
| Negative | 255 | 9 | 3 | 6 | 6 | |||
| Histology | ||||||||
| DCIS | 3 | 0 | 1.00 | 0 | 1.00 | 0 | 0.52 | 0 |
| Invasive ductal carcinoma | 341 | 8 | 3 | 5 | 8 | |||
| Other Invasive carcinomas | 41 | 1 | 0 | 1 | 0 | |||
| Histological grade | ||||||||
| I/II | 126 | 2 | 0.50 | 1 | 1.00 | 1 | 0.67 | 2 |
| III | 230 | 7 | 2 | 5 | 6 | |||
| T | ||||||||
| Tis/T1 | 128 | 0 | 0.10 | 0 | 0.65 | 0 | 0.30 | 1 |
| T2 | 227 | 9 | 3 | 6 | 7 | |||
| T3 | 17 | 0 | 0 | 0 | 0 | |||
| T4 | 11 | 0 | 0 | 0 | 0 | |||
| No. of lymph node involvement | ||||||||
| 0 | 166 | 4 | 0.56 | 2 | 0.45 | 2 | 0.77 | 2 |
| 1~3 | 133 | 2 | 0 | 2 | 2 | |||
| ≥4 | 85 | 3 | 1 | 2 | 4 | |||
| M | ||||||||
| M0 | 381 | 9 | 1.00 | 3 | 1.00 | 6 | 1.00 | 8 |
| M1 | 3 | 0 | 0 | 0 | 0 | |||
| Clinical stage | ||||||||
| 0/I | 60 | 0 | 0.48 | 0 | 1.00 | 0 | 0.74 | 1 |
| II | 227 | 6 | 2 | 4 | 3 | |||
| III | 93 | 3 | 1 | 2 | 4 | |||
| VI | 3 | 0 | 0 | 0 | 0 | |||
| Standard therapy | ||||||||
| Yes | 370 | 38 | 0.67 | 18 | 1.00 | 20 | 0.23 | 58 |
| No | 15 | 2 | 0 | 2 | 4 | |||
a P-value calculated comparing with non-carriers by two-tailed t-tests and Fisher's Exact tests as appropriate. Unknown data were not included in the analysis.